TLPHNasdaq

TALPHERA, INC.

Healthcare·Infectious Disease·Phase 3·San Mateo, CA, United States
Infectious DiseaseRespiratoryHematologyNephrologyGastroenterology

TALPHERA, INC. (TLPH): 2 pipeline candidates · ~18 mo cash runway · 1 clinical trial. Updated within the last hour.

7.4/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway5.0

17.9 months

Financial Health9.1

D/E 0.63 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider Signal10.0

5 buys · 0 sells (180d)

A transparent, data-derived signal for TALPHERA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$45.9M

Cash

$3.8M

Quarterly Burn

$3.4M

Runway

17.9 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Dec 2027
Today~20 mo out
Catalyst within runway

Pipeline (2 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

39

Total value held

$5.9M

HolderSharesValue
rock springs capital management lp3,589,186$2.7M
cantor fitzgerald, l. p.887,481$663K
vanguard capital management llc883,222$660K
dauntless investment group, llc435,234$325K
geode capital management, llc419,980$314K
shay capital llc250,083$187K
renaissance technologies llc237,755$178K
citadel advisors llc216,451$162K
vanguard fiduciary trust co192,405$144K
diadema partners lp153,563$115K

Showing top 10 of 39 institutional holders of TALPHERA, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

1 clinical trial·CEO: Mr. Vincent J. Angotti

Frequently asked questions

How many drug candidates are in TALPHERA, INC.'s pipeline?

TALPHERA, INC. (TLPH) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is TALPHERA, INC.'s lead drug candidate?

TALPHERA, INC.'s most advanced tracked candidate is ltx-608 (Preclinical) for Antiviral treatment, or treatment of ARDS, DIC or acute pancreatitis.

What is TALPHERA, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, TALPHERA, INC. has approximately 17.9 months of cash runway.

What is TALPHERA, INC.'s market capitalization?

TALPHERA, INC.'s market capitalization is approximately $45.9M.

Who is the CEO of TALPHERA, INC.?

Mr. Vincent J. Angotti is the chief executive officer of TALPHERA, INC. (TLPH).

Get the full picture on TALPHERA, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.